Lepu Biopharma (HKG:2157) has renewed a procurement agreement with controlling shareholder Lepu Medical Technology (SHE:300003) for one year from Jan. 1 to Dec. 31, 2025, a Tuesday bourse filing said.

Under the contract, Lepu Medical Technology, alongside its units and associates, will continue supplying raw materials and supplementary materials for clinical trials, biological sample test services for clinical trials, employee body check services, and other products to the company.

The current procurement framework agreement is due to expire Dec. 31, according to the drugmaker.